Low Darunavir Exposure during Pregnancy with 800/100mg Darunavir/r QD Dosings

CONCLUSIONS

If DRV/r 3rd trimester had been used (n=7) postpartum GM ratio was 1.03 (0.79-1.35) for pregnant women treated with DRV/r during pregnancy. DRV/r was well tolerated and safe for pregnant women and infants. We recommend the use of DRV/r 3rd trimester / postpartum for pregnant women with an effective cART regimen.

ACKNOWLEDGEMENTS

We wish to thank the following people that participated in the postpartum arm of the study: Angela Colbers, Jelena Ivanovic, David Hawkins, Tariq Saddi, Babamara Kabeya, Andrea Gingelmaier, Katharina Weisskogel, Graham Taylor, David Burger. This work is conducted on behalf of the PANNNA network.

REFERENCES

1. Veldhuijzen, J; Mies J; van den Bosh J; Friesema P; van Griensven B; van der Geest J. Pregnancy and Antiretroviral Therapy (PARTNER) trial: a randomized controlled trial comparing efavirenz with darunavir/cobicistat as part of optimized background regimen in pregnant women with HIV-1 infection. PLoS Med. 2017;14(1):e1002238.


